Educational & Equity Implications of Biomarker Testing & Targeted Therapy Access in NSCLC
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Presenter: Shawnny Eugene, PharmD, MBA, MS | NCODA
Differences in education, resources, and access can influence whether biomarker testing leads to timely targeted therapy in advanced non-small cell lung cancer.
In this CE-accredited session, Shawnny Eugene, PharmD, MBA, MS, will examine current biomarker testing and targeted therapy workflows in advanced NSCLC and explore the equity considerations that can affect access to care.
Learning Objectives:
- Describe current biomarker testing and targeted therapy workflows in advanced non-small cell lung cancer
- Investigate the methodology and assumptions used in “Educational and Equity Implications of Biomarker Testing and Targeted Therapy Access in NSCLC”
- Summarize key findings from the article related to testing, treatment access, and documentation
- Relate the significance of the findings from the article to oncology practice management, workflow design, and quality improvement
This activity has been approved for CE credit for pharmacists and pharmacy technicians only.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Additional Upcoming Webinars
March 25, 2026 | 5:00 PM
March 26, 2026 | 2:00 PM
Upcoming Webinar
Pharmacy Perspectives: Exploring Limited Distribution in Oncology
March 31, 2026 | 5:00 PM